Physician profile
Kathryn A Hedges
NPI 1427091776
$17,118.75
in general payments reported to CMS, 2019-2025
67 companies · $3,307 in 2025
The $3,307 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,328 · 2020: $826 · 2021: $812 · 2022: $2,819 · 2023: $3,527 · 2024: $4,499 · 2025: $3,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $1,192 · Education: $91.25 · Travel and Lodging: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,016.44 |
| Consulting Fee | $1,191.90 |
| Education | $91.25 |
| Travel and Lodging | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,674.45 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $1,371.47 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Biogen, INC. | $1,258.84 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Teva Pharmaceuticals USA, INC. | $1,133.67 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Emd Serono, INC. | $997.48 | 2019-2025 | Mavenclad, Mavenclad |
| Pfizer INC. | $922.07 | 2019-2025 | |
| Lilly USA, LLC | $700.00 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Genentech USA, INC. | $513.95 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Celgene Corporation | $466.58 | 2022-2025 | Zeposia |
| Lundbeck LLC | $459.20 | 2019-2025 | Vyepti, Rexulti |
| Ucb, INC. | $454.31 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $408.61 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $369.06 | 2019-2025 | |
| Eisai INC. | $354.42 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $268.71 | 2022 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Hedges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.